猴痘的临床表现与诊疗随访

doi:10.35541/cjd.20220688

Abstract

Abstract: 【Abstract】 The world is suffering from the monkeypox epidemic, and China is facing a great risk of monkeypox importation. Understanding and mastering clinical manifestations, diagnosis and treatment of monkeypox is one of the important measures to respond to future crises. This review summarizes updated guidelines and relevant studies, and covers main clinical manifestations, diagnosis, treatment and follow-up of monkeypox patients, as well as management of special populations, aiming to provide references for clinicians and prevention workers.

Key words: Monkeypox, Diagnosis, Treatment

Du Fangzhi, Zhang Xu, Wang Qianqiu. Monkeypox: clinical manifestations, diagnosis, treatment and follow-up[J]. Chinese Journal of Dermatology, 2023, 56(1): 76-81.doi:10.35541/cjd.20220688

References ［43］

［1］	Shchelkunov SN, Totmenin AV, Babkin IV, et al. Human monkeypox and smallpox viruses: genomic comparison［J］. FEBS Lett, 2001,509（1）:66⁃70. doi: 10.1016/s0014⁃5793（01）03144⁃1.
［2］	McCollum AM, Damon IK. Human monkeypox［J］. Clin Infect Dis, 2014,58（2）:260⁃267. doi: 10.1093/cid/cit703.
［3］	American College of Emergency Physicians. ACEP monkeypox field guide［EB/OL］. （2022⁃07⁃08）［2022⁃11⁃02］. https://www.acep.org/monkeypox⁃field⁃guide/cover⁃page/.
［4］	Centers for Disease Control and Prevention. About Monkeypox［EB/OL］. （Updated 2022⁃07⁃22）［2022⁃11⁃02］. https://www.cdc.gov/poxvirus/monkeypox/about.html.
［5］	Bunge EM, Hoet B, Chen L, et al. The changing epidemiology of human monkeypox⁃a potential threat? A systematic review［J/OL］. PLoS Negl Trop Dis, 2022,16（2）:e0010141. doi: 10.1371/journal.pntd.0010141.
［6］	Di Giulio DB, Eckburg PB. Human monkeypox: an emerging zoonosis［J］. Lancet Infect Dis, 2004,4（1）:15⁃25. doi: 10.1016/s1473⁃3099（03）00856⁃9.
［7］	Thornhill JP, Barkati S, Walmsley S, et al. Monkeypox virus infection in humans across 16 countries ⁃ April⁃June 2022［J］. N Engl J Med, 2022,387（8）:679⁃691. doi: 10.1056/NEJMoa22 07323.
［8］	Orviz E, Negredo A, Ayerdi O, et al. Monkeypox outbreak in Madrid （Spain）: clinical and virological aspects［J］. J Infect, 2022,85（4）:412⁃417. doi: 10.1016/j.jinf.2022.07.005.
［9］	Jezek Z, Szczeniowski M, Paluku KM, et al. Human monkeypox: clinical features of 282 patients［J］. J Infect Dis, 1987,156（2）:293⁃298. doi: 10.1093/infdis/156.2.293.
［10］	Yinka⁃Ogunleye A, Aruna O, Dalhat M, et al. Outbreak of human monkeypox in Nigeria in 2017⁃18: a clinical and epidemiological report［J］. Lancet Infect Dis, 2019,19（8）:872⁃879. doi: 10.1016/S1473⁃3099（19）30294⁃4.
［11］	Centers for Disease Control and Prevention. Case definitions for use in the 2022 monkeypox response［EB/OL］. （Updated 2022⁃07⁃22）［2022⁃11⁃02］. https://www.cdc.gov/poxvirus/monkeypox/clinicians/case⁃definition.html.
［12］	Peterson E, Kantele A, Koopmans M, et al. Human monkeypox: epidemiological and clinical characteristics, diagnosis, and prevention［J］. Infect Dis Clin North Am, 2019,33（4）:1027⁃1043. doi: 10.1016/j.idc.2019.03.001.
［13］	Osadebe L, Hughes CM, Shongo Lushima R, et al. Enhancing case definitions for surveillance of human monkeypox in the Democratic Republic of Congo［J］. PLoS Negl Trop Dis, 2017,11（9）:e0005857. doi: 10.1371/journal.pntd.0005857.
［14］	Singhal T, Kabra SK, Lodha R. Monkeypox: a review［J］. Indian J Pediatr, 2022,89（10）:955⁃960. doi: 10.1007/s12098⁃022⁃04348⁃0.
［15］	Patel A, Bilinska J, Tam J, et al. Clinical features and novel presentations of human monkeypox in a central London centre during the 2022 outbreak: descriptive case series［J］. BMJ, 2022,378:e072410. doi: 10.1136/bmj⁃2022⁃072410.
［16］	Tarín⁃Vicente EJ, Alemany A, Agud⁃Dios M, et al. Clinical presentation and virological assessment of confirmed human monkeypox virus cases in Spain: a prospective observational cohort study［J］. Lancet, 2022,400（10353）:661⁃669. doi: 10. 1016/S0140⁃6736（22）01436⁃2.
［17］	Australian Government Department of Heath and Aged Care. Australian national notifiable diseases case definition［EB/OL］. （2022⁃08⁃01）［2022⁃11⁃02］. https://www.health.gov.au/resources/publications/monkeypox⁃virus⁃infection⁃surveillance⁃case⁃definition.
［18］	European Centre for Disease Prevention and Control, World Health Organization European Region. Joint ECDC⁃WHO regional office for Europe monkeypox surveillance bulletin［EB/OL］. （2022⁃09⁃21）［2022⁃11⁃02］. https://www.who.int/europe/publications/m/item/joint⁃ecdc⁃who⁃regional⁃office⁃for⁃europe⁃monkeypox⁃surveillance⁃bulletin⁃⁃21⁃september⁃2022.
［19］	World Heath Organization. Clinical management and infection prevention and control for monkeypox: interim rapid response guidance［EB/OL］. （2022⁃06⁃10）［2022⁃11⁃02］. https://www.who.int/publications/i/item/WHO⁃MPX⁃Clinical⁃and⁃IPC⁃2022.1.
［20］	中华人民共和国国家卫生健康委员会. 猴痘诊疗指南（2022年版）［EB/OL］. （2022⁃06⁃14）［2022⁃11⁃02］. http://www.nhc.gov.cn/yzygj/s7653p/202206/d687b12fe8b84bbfaede2c7a5ca596ec.
	shtml.
［21］	Vaughan AM, Cenciarelli O, Colombe S, et al. A large multi⁃country outbreak of monkeypox across 41 countries in the WHO European Region, 7 March to 23 August 2022［J］. Euro Surveill, 2022,27（36）. doi: 10.2807/1560⁃7917.ES.2022.27.36.2200620.
［22］	Kannan S, Shaik Syed Ali P, Sheeza A. Monkeypox: epidemiology, mode of transmission, clinical features, genetic clades and molecular properties［J］. Eur Rev Med Pharmacol Sci, 2022,26（16）:5983⁃5990. doi: 10.26355/eurrev_202208_29540.
［23］	Harris E. What to know about monkeypox［J］. JAMA, 2022,327（23）:2278⁃2279. doi: 10.1001/jama.2022.9499.
［24］	Tutu van Furth AM, van der Kuip M, van Els AL, et al. Paediatric monkeypox patient with unknown source of infection, the Netherlands, June 2022［J］. Euro Surveill, 2022,27（29）. doi: 10.2807/1560⁃7917.ES.2022.27.29.2200552.
［25］	Damon IK. Status of human monkeypox: clinical disease, epidemiology and research［J］. Vaccine, 2011,29 Suppl 4:D54⁃59. doi: 10.1016/j.vaccine.2011.04.014.
［26］	Adler H, Gould S, Hine P, et al. Clinical features and management of human monkeypox: a retrospective observational study in the UK［J］. Lancet Infect Dis, 2022,22（8）:1153⁃1162. doi: 10.1016/S1473⁃3099（22）00228⁃6.
［27］	Stern D, Olson VA, Smith SK, et al. Rapid and sensitive point⁃of⁃care detection of Orthopoxviruses by ABICAP immunofiltration［J］. Virol J, 2016,13（1）:207. doi: 10.1186/s12985⁃016⁃0665⁃5.
［28］	Diaz JH. The disease ecology, epidemiology, clinical manifestations, management, prevention, and control of increasing human infections with animal ortho poxviruses［J］. Wilderness Environ Med, 2021,32（4）:528⁃536. doi: 10.1016/j.wem.2021.08.003.
［29］	Patil A, Goldust M, Wollina U. Herpes zoster: a review of clinical manifestations and management［J］. Viruses, 2022,14（2）. doi: 10.3390/v14020192.
［30］	Hoff NA, Morier DS, Kisalu NK, et al. Varicella coinfection in patients with active monkeypox in the Democratic Republic of the Congo［J］. Ecohealth, 2017,14（3）:564⁃574. doi: 10.1007/s10393⁃017⁃1266⁃5.
［31］	Ramoni S, Maronese CA, Morini N, et al. Syphilis and monkeypox co⁃infection: coincidence, synergy or asymptomatic carriage?［J］. Travel Med Infect Dis, 2022,50:102447. doi: 10.1016/j.tmaid.2022.102447.
［32］	Sherwat A, Brooks JT, Birnkrant D, et al. Tecovirimat and the treatment of monkeypox ⁃ past, present, and future considerations［J］. N Engl J Med, 2022,387（7）:579⁃581. doi: 10.1056/NEJMp2210125.
［33］	Desai AN, Thompson GR 3rd, Neumeister SM, et al. Compassionate use of tecovirimat for the treatment of monkeypox infection［J］. JAMA, 2022,328（13）:1348⁃1350. doi: 10.1001/jama.2022.15336.
［34］	De Clercq E. Cidofovir in the therapy and short⁃term prophylaxis of poxvirus infections［J］. Trends Pharmacol Sci, 2002,23（10）:456⁃458. doi: 10.1016/s0165⁃6147（02）02091⁃6.
［35］	Khawaja F, Batista MV, El Haddad L, et al. Resistant or refractory cytomegalovirus infections after hematopoietic cell trans⁃plantation: diagnosis and management［J］. Curr Opin Infect Dis, 2019,32（6）:565⁃574. doi: 10.1097/QCO.0000000000000607.
［36］	Berhanu A, King DS, Mosier S, et al. Impact of ST⁃246® on ACAM2000™ smallpox vaccine reactogenicity, immunogenicity, and protective efficacy in immunodeficient mice［J］. Vaccine, 2010,29（2）:289⁃303. doi: 10.1016/j.vaccine.2010.10.039.
［37］	Russo AT, Berhanu A, Bigger CB, et al. Co⁃administration of tecovirimat and ACAM2000™ in non⁃human primates: effect of tecovirimat treatment on ACAM2000 immunogenicity and efficacy versus lethal monkeypox virus challenge［J］. Vaccine, 2020,38（3）:644⁃654. doi: 10.1016/j.vaccine.2019.10.049.
［38］	Perez Duque M, Ribeiro S, Martins JV, et al. Ongoing monkeypox virus outbreak, Portugal, 29 April to 23 May 2022［J］. Euro Surveill, 2022,27（22）. doi: 10.2807/1560⁃7917.ES.2022.27.22.2200424.
［39］	Iñigo Martínez J, Gil Montalbán E, Jiménez Bueno S, et al. Monkeypox outbreak predominantly affecting men who have sex with men, Madrid, Spain, 26 April to 16 June 2022［J］. Euro Surveill, 2022,27（27）. doi: 10.2807/1560⁃7917.ES.2022.27.27. 2200471.
［40］	UK Health Security Agency. Investigation into monkeypox outbreak in England: technical briefing 3［EB/OL］. （Updated 2022⁃09⁃23）［2022⁃11⁃02］. https://www.gov.uk/government/publications/monkeypox⁃outbreak⁃technical⁃briefings/investigation⁃into⁃monkeypox⁃outbreak⁃in⁃england⁃technical⁃briefing⁃3.
［41］	Hoffmann C, Jessen H, Wyen C, et al. Clinical characteristics of monkeypox virus infections among men with and without HIV: a large outbreak cohort in Germany［J］. HIV Med, 2022. doi: 10.1111/hiv.13378.
［42］	Mbala PK, Huggins JW, Riu⁃Rovira T, et al. Maternal and fetal outcomes among pregnant women with human monkeypox infection in the Democratic Republic of Congo［J］. J Infect Dis, 2017,216（7）:824⁃828. doi: 10.1093/infdis/jix260.
［43］	Marshall BC, Koch WC. Antivirals for cytomegalovirus infection in neonates and infants: focus on pharmacokinetics, formulations, dosing, and adverse events［J］. Paediatr Drugs, 2009,11（5）:309⁃321. doi: 10.2165/11316080⁃000000000⁃00000.

[1]	Chen Qitao, Li Yuqian, Shao Guanghui, Zhu Jing, Zhu Qilin, Li Zhongming, Du Xufeng, Fan Weixin. Erosive pustular dermatosis of the scalp [J]. Chinese Journal of Dermatology, 2023, 0(2): 20210803-e20210803.
[2]	Rosacea Research Center, Chinese Society of Dermatology, Rosacea Professional Committee, China Dermatologist Association. Expert consensus on intradermal injections with botulinum toxin A for the treatment of flushing and persistent erythema caused by rosacea [J]. Chinese Journal of Dermatology, 2023, 56(1): 16-21.
[3]	Li Wei, Li Zheng . Atopic dermatitis with typical and atypical manifestations [J]. Chinese Journal of Dermatology, 2023, 56(1): 1-4.
[4]	Lei Jiehao, Hong Weisong, Lin Fuquan, Hu Wenting, Xu Ai′e. In vitro culture of melanocytes from segmental vitiligo-like nevus depigmentosus lesions and its clinical significance [J]. Chinese Journal of Dermatology, 2022, 55(9): 798-802.
[5]	Lyu Sha, Wang Shuang, Wu Hanfei, Zhang Mingrui, Hu Xin, Li Fuqiu. Research progress in sporotrichosis [J]. Chinese Journal of Dermatology, 2022, 55(7): 629-632.
[6]	Gao Zirui, Zhao Pei, Dou Yuanqing, Liu Ping, Zhang Jianzhong. Efficacy and safety of dupilumab in the treatment of adult prurigo nodularis [J]. Chinese Journal of Dermatology, 2022, 55(7): 562-565.
[7]	Wang Lingyan, Pan Jing, Miao Gang, Chang Xiaodan, Jin Qiuzi, Guo Ningning, Zhang Jiayu. Analysis of difficult-to-treat sites in patients with psoriasis who received biological therapy [J]. Chinese Journal of Dermatology, 2022, 55(7): 583-587.
[8]	Huang Xin, Chen Xiaoyun, Li Yaping, Liang Xingkun, Zhang Guiying, Zhou Ying, Zhan Yi, Luo Shuaihantian, Liao Jieyue, Xiao Rong, Long Hai. Efficacy and safety of dupilumab in the treatment of 123 cases of atopic dermatitis [J]. Chinese Journal of Dermatology, 2022, 55(6): 486-493.
[9]	Hu Yebei, Song Xiuzu. Tranexamic acid for the treatment of melasma [J]. Chinese Journal of Dermatology, 2022, 55(5): 460-462.
[10]	Luo Shuaihantian, Long Hai, Lu Qianjin, . Research advances in systemic lupus erythematosus in 2021 [J]. Chinese Journal of Dermatology, 2022, 55(4): 369-372.
[11]	Li Yan, Li Ming, Xu Wei, Li Linfeng. Calcium-based antimicrobial peptide compounds cooling gel for the treatment of atopic dermatitis: a randomized, double-blind controlled clinical study [J]. Chinese Journal of Dermatology, 2022, 55(4): 345-348.
[12]	Liu Bo, Song Xiaoting, Liao Shuanglu, Yu Miao, Luan Tingting, Li Ruoyu, Zhao Zuotao. Efficacy and safety of baricitinib in the treatment of moderate-to-severe atopic dermatitis: a clinical observation [J]. Chinese Journal of Dermatology, 2022, 55(4): 304-307.
[13]	Centre for Urticaria Research, Chinese Society of Dermatology. Guidelines for education of patients with chronic urticaria (2022) [J]. Chinese Journal of Dermatology, 2022, 0(4): 20220305-e20220305.
[14]	Wang Min, He Pingxiu, Cheng Lifang, Hong Kechun, Ai Yong. A case of meningothelial hamartoma of the scalp [J]. Chinese Journal of Dermatology, 2022, 0(3): 20210080-e20210080.
[15]	Li Yan, Li Ming, Xu Wei, Li Linfeng. Efficacy of fluticasone propionate cream alone or in combination with calcipotriol ointment in the treatment of mild to moderate plaque psoriasis: a randomized self-controlled study [J]. Chinese Journal of Dermatology, 2022, 55(3): 260-263.

Monkeypox: clinical manifestations, diagnosis, treatment and follow-up

PDF

Knowledge

Abstract

Cite this article

share this article

References ［43］

Related Articles 15

Metrics

Comments

Recommended 10